Self-Assembling Tacrolimus Nanomicelles for Retinal Drug Delivery

Area of Science:

• Ophthalmology
• Nanotechnology
• Pharmacology

Background:

• Neovascular age-related macular degeneration (AMD) involves increased reactive oxygen species (ROS) and inflammation in retinal pigment epithelium.
• Current treatments for AMD face challenges in drug delivery and efficacy.

Purpose of the Study:

• Develop a clear tacrolimus nanomicellar formulation (TAC-NMF) for treating AMD.
• Evaluate the efficacy of TAC-NMF in reducing oxidative stress and inflammation in ocular models.

Main Methods:

• Formulation of TAC-NMF with optimized particle size and high entrapment efficiency.
• In-vitro cytotoxicity, cellular uptake, and distribution studies on ocular cell lines.
• Assessment of ROS and pro-inflammatory cytokine levels (IL-6, IL-1β, TNF-α, VEGF-A) in treated cells.

Main Results:

• Optimized TAC-NMF exhibited a mean diameter of 15.41 nm and 97.13% entrapment efficiency.
• TAC-NMF demonstrated dose-dependent cytotoxicity and time-dependent cellular uptake.
• Treatment with TAC-NMF significantly reduced ROS, pro-inflammatory cytokines, and VEGF-A in AMD-relevant cellular models.

Conclusions:

• TAC-NMF is a promising clear formulation for AMD treatment.
• The nanomicellar formulation effectively mitigates key pathological factors in AMD, including oxidative stress and inflammation.
• Further investigation into TAC-NMF's therapeutic potential in AMD is warranted.